Gilead Sciences, Inc. (NASDAQ:GILD) is among the most profitable healthcare stocks to buy. On January 26, UBS lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) from $145 to $155 and maintained a Buy rating, according to TheFly. Slightly below the consensus 1-year high price target, the revised target implies nearly 12% upside.
From appealing valuations and light positioning to supporting drug-pricing overhangs and sustained pharma-led M&A activity, there are many reasons to believe in the strong performance of the U.S. Pharmaceuticals and Biotechnology group, the analyst noted. UBS noted that although there are worries regarding the conservative guidance, particularly after the recent rally, inexpensive valuations for big pharma and biotech are expected to continue positive money flows into the sector.
Copyright: dolgachov / 123RF Stock Photo
On the same day, BMO Capital also raised its target on Gilead Sciences, Inc. (NASDAQ:GILD) to $150 from $135 and reiterated an Outperform rating on the stock. While highlighting the Yeztugo launch, which achieved $150 million in FY25 sales, the firm cited strong momentum in the company’s HIV business.
Gilead Sciences, Inc. (NASDAQ:GILD) is a California-based biopharmaceutical company specializing in medicines aimed at unmet needs. Founded in 1987, the company provides a range of products as solutions for HIV/AIDS, COVID-19, viral hepatitis, oncology, pulmonary arterial hypertension, and serious invasive fungal infections.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
-1024x683.jpg "Michigan – The Sum of Democrat Fears")
